5-HT3-receptor antagonists for the treatment of nausea and vomiting: A reappraisal of their side-effect profile

Oncologist

Volumn 7, Issue 5, 2002, Pages 424-436

  Goodin, Susan ^a,b   Cunningham, Regina ^a  

^a RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

5 HT3 receptor antagonists; Dolasetron; Emesis; Granisetron; Ondansetron; Side effects

Indexed keywords

ANTIHISTAMINIC AGENT; BELLADONNA ALKALOID; BENZAMIDE DERIVATIVE; BENZODIAZEPINE DERIVATIVE; BENZQUINAMIDE; CANNABINOID; CHLORPROMAZINE; CORTICOSTEROID; DEXAMETHASONE; DIPHENHYDRAMINE; DOLASETRON MESILATE; DRONABINOL; DROPERIDOL; GRANISETRON; HALOPERIDOL; HYDROXYZINE; LORAZEPAM; METHYLPREDNISOLONE; METOCLOPRAMIDE; ONDANSETRON; PHENOTHIAZINE DERIVATIVE; PROCHLORPERAZINE; PROMETHAZINE; SCOPOLAMINE; SEROTONIN 3 ANTAGONIST; TRIETHYLPERAZINE; TRIMETHOBENZAMIDE;

AMNESIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; CANCER; CANCER CHEMOTHERAPY; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; CONSTIPATION; DROWSINESS; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; EUPHORIA; EXTRAPYRAMIDAL SYMPTOM; FLUSHING; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HEADACHE; HUMAN; HYPERPROLACTINEMIA; HYPOTENSION; INJECTION PAIN; INSOMNIA; MYALGIA; NAUSEA; NEUROLEPTIC MALIGNANT SYNDROME; PRIORITY JOURNAL; TREMOR; VERTIGO; VISUAL IMPAIRMENT; VOMITING; XEROSTOMIA;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; HUMANS; NAUSEA; NEOPLASMS; RADIOTHERAPY; SEROTONIN ANTAGONISTS; SURGICAL PROCEDURES, OPERATIVE; VOMITING;

EID: 0036413427     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.7-5-424     Document Type: Article

References (82)

1. ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health Syst Pharm 1999;56:729-764.
2. Gralla RJ, Osoba D, Kris MG et al. Recommendations for the use of antiemetics: Evidence-based, clinical practice guidelines. J Clin Oncol 1999;17:2971-2994.
3. Ettinger DS, Huber S, Kris MG et al. NCCN antiemesis practice guidelines. Oncology (Huntingt) 1997;11:57-89.
4. 3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting. Cancer Invest 2000;18:163-173.
5. Verweij J, de Wit R, de Mulder PHM. Optimal control of acute cisplatin-induced emesis. Oncology 1996;53(suppl 1):56-64.
6. Aleksandrovic J, Dagovic A, Jeremic B. [Modern aspects of antiemetic therapy.] Srp Arh Celok Lek 1998;126:295-303 Serbo-Croatian (Cyrillic).
7. Morrow GR, Hickok JT, Rosenthal SN. Progress in reducing nausea and emesis. Comparisons of ondansetron (Zofran), granisetron (Kytril), and tropisetron (Navoban). Cancer 1995;76:343-357.
8. Chevallier B. Efficacy and safety of granisetron compared with high-dose metoclopramide plus dexamethasone in patients receiving high-dose cisplatin in a single-blind study. The Granisetron Study Group. Eur J Cancer 1990;26(suppl 1):S33-S36.
9. Fauser AA, Bleiberg H, Chevallier B et al. A double-blind, randomized, parallel study of IV dolasetron mesilate versus IV metoclopramide in patients receiving moderately emetogenic chemotherapy. Cancer J 1996;9:196-202.
10. 3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med 1990;322:816-821.
11. De Mulder PHM, Seynaeve C, Vermorken JB et al. Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting; a multicenter, randomized, double-blind crossover study. Ann Intern Med 1990;113:834-840.
12. Abbott B, Ippoliti C, Hecth D et al. Granisetron (Kytril) plus dexamethasone for antiemetic control in bone marrow transplant patients receiving highly emetogenic chemotherapy with or without total body irradiation. Bone Marrow Transplant 2000;25:1279-1283.
13. Herrington JD, Kwan P, Young RR et al. Randomized, multicenter comparison of oral granisetron and oral ondansetron for emetogenic chemotherapy. Pharmacotherapy 2000;20:1318-1323.
14. Lofters WS, Pater JL, Zee B et al. Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy. J Clin Oncol 1997;15:2966-2973.
15. Olver I, Paska W, Depierre A et al. A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ann Oncol 1996;7:945-952.
16. Sigsgaard T, Herrstedt J, Handberg J et al. Ondansetron plus metopimazine compared with ondansetron plus metopimazine plus prednisolone as antiemetic prophylaxis in patients receiving multiple cycles of moderately emetogenic chemotherapy. J Clin Oncol 2001;19:2091-2097.
17. Uchida K, Akaza H, Shimazui T et al. [Comparison of clinical effects between granisetron alone and combination of granisetron plus methylprednisolone against the nausea and vomiting induced by CDDP chemotherapy: Comparative study by the cross-over trial. Gan To Kagaku Ryoho 1996;23:81-86 (Japanese).
18. Anzemet® (Dolasetron Mesylate) Prescribing Information. Kansas City, MO: Aventis Pharmaceuticals Inc., 2000.
19. Zofran® (ondansetron hydrochloride) Prescribing Information. Research Triangle Park, NC: GlaxoSmithKline, 2001.
20. Kytril® (Granisetron Hydrochloride) Prescribing Information. Nutley, NJ: Roche Laboratories Inc., 2000.
21. 3 receptor antagonist drugs. In: Dubois A, King GL, Livengood DR, eds. Radiation and the GI Tract. Boca Raton, FL: CRC Press Inc., 1995:37-49.
22. van Wijngaarden I, Tulp MT, Soudijn W. The concept of selectivity in 5-HT receptor research. Eur J Pharmacol 1990;188:301-312.
23. Hesketh P, Navari R, Grote T et al. Double-bind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. J Clin Oncol 1996;14:2242-2249.
24. Perez EA, Hesketh P, Sandbach J et al. Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: A multicenter, double-blind, randomized parallel study. J Clin Oncol 1998;16:754-760.
25. Veneziano M, Framarino Dei Malatesta M, Bandiera AF et al. Ondansetron-induced headache. Our experience in gynecological cancer. Eur J Gynaecol Oncol 1995;16:203-207.
26. Perez EA, Lembersky B, Kaywin P et al. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy. Cancer J Sci Am 1998;4:52-58.
27. Ettinger DS. Preventing chemotherapy-induced nausea and vomiting: An update and a review of emesis. Semin Oncol 1995;22(suppl 10):6-18.
28. Audhuy B, Cappelaere P, Martin M et al. A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy. Eur J Cancer 1996;32A:807-813.
29. Benedict CR, Arbogast R, Martin L et al. Single-blind study of the effects of intravenous dolasetron mesylate versus ondansetron on electrocardiographic parameters in normal volunteers. J Cardiovasc Pharmacol 1996;28:53-59.
30. Boike SC, Ilson B, Zariffa N et al. Cardiovascular effects of i.v. granisetron at two administration rates and of ondansetron in healthy adults. Am J Health Syst Pharm 1997;54:1172-1176.
31. Jantunen IT, Kataja VV, Muhonen TT et al. Effects of granisetron with doxorubicin or epirubicin on ECG intervals. Cancer Chemother Pharmacol 1996;37:502-504.
32. Lifsey DS, Gralla RJ, Clark RA et al. Electrocardiographic changes with serotonin antagonistic antiemetics. Rate of occurrence and clinical relevance. Proc Am Soc Clin Oncol 1993;12:463a.
33. Watanabe H, Hasegawa A, Shinozaki T et al. Possible cardiac side effects of granisetron, an antiemetic agent, in patients with bone and soft-tissue sarcomas receiving cytotoxic chemotherapy. Cancer Chemother Pharmacol 1995;35:278-282.
34. Hunt TL, Cramer M, Shah A et al. A double-blind, placebo-controlled, dose-ranging safety evaluation of single-dose intravenous dolasetron in healthy male volunteers. J Clin Pharmacol 1995;35:705-712.
35. c prolongation measured by standard 12-lead electrocardiography is an independent risk factor for sudden death due to cardiac arrest. Circulation 1991;83:1888-1894.
36. Baltzer L, Kris MG, Hinkley L et al. Reversible electrocardiographic interval prolongations following the specific serotonin antagonists ondansetron (OND) and dolasetron mesylate (DM): A possible drug class effect without sequelae? Proc Am Soc Clin Oncol 1994;13:433a.
37. Oshiro MM. Dolasetron-associated venous irritation. Am J Health Syst Pharm 2000;57:1533-1534.
38. Oge A, Alkis N, Oge O et al. Comparison of granisetron, ondansetron and tropisetron for control of vomiting and nausea induced by cisplatin. J Chemother 2000;12:105-108.
39. Ernst E, Cassileth BR. The prevalence of complementary/alternative medicine in cancer: A systematic review. Cancer 1998;83:777-782.
40. Davis MP, Homsi J. The importance of cytochrome P450 monooxygenase CYP2D6 in palliative medicine. Support Care Cancer 2001;9:442-451.
41. Wood M. Pharmacokinetic drug interactions in anaesthetic practice. Clin Pharmacokinet 1991;21:285-307.
42. 3 antagonists (granisetron, ondansetron and tropisetron) plus dexamethasone for the prevention of cisplatin-induced acute emesis: A randomized crossover study. Am J Clin Oncol 2000;23:185-191.
43. Hoehn-Saric R, McLeod DR. Cardiac symptoms and anxiety disorders: Contributing factors and pharmacologic treatment. Am J Cardiol 1987;60:68J-73J.
44. Wei JY. Cardiovascular comorbidity in the older cancer patient. Semin Oncol 1995;22(suppl 1):9-10.
45. Ryberg M, Nielsen D, Skovsgaard T et al. Epirubicin cardiotoxicity: An analysis of 469 patients with metastatic breast cancer. J Clin Oncol 1998;16:3502-3508.
46. Faulds D, Balfour JA, Chrisp P et al. Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. Drugs 1991;41:400-449.
47. DuKart G, Iatropoulos MJ, Yacobi A. Comment on mitoxantrone. Drug Intell Clin Pharm 1985;19:216-218.
48. Poirier TI. Mitoxantrone. Drug Intell Clin Pharm 1986;20:97-105.
49. McGuire WP, Rowinsky EK, Rosenshein NB et al. Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989;111:273-279.
50. Rowinsky EK, Donehower RC. Paclitaxel (Taxol). N Engl J Med 1995;332:1004-1014.
51. Lowenthal RM, Eaton K. Toxicity of chemotherapy. Hematol Oncol Clin North Am 1996;10:967-990.
52. Krischer JP, Epstein S, Cuthbertson DD et al. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: The Pediatric Oncology Group experience. J Clin Oncol 1997;15:1544-1552.
53. Keefe DL, Roistacher N, Pierri MK. Clinical cardiotoxicity of 5-fluorouracil. J Clin Pharmacol 1993;33:1060-1070.
54. Braverman AC, Antin JH, Plappert MT et al. Cyclophosphamide cardiotoxicity in bone marrow transplantation: A prospective evaluation of new dosing regimens. J Clin Oncol 1991;9:1215-1223.
55. Ohnishi K, Yoshida H, Shigeno K et al. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. Ann Intern Med 2000;133:881-885.
56. Oppenheim MH, Lotze MT. Interleukin-2: Solid-tumor therapy. Oncology 1994;51:154-169.
57. Stewart JR, Fajardo LF, Gillette SM et al. Radiation injury to the heart. Int J Radiat Oncol Biol Phys 1995;31:1205-1211.
58. National Cancer Institute. Surveillance, Epidemiology and End Results: 1999 Estimated US Prevalence Counts. Available at: http://www-seer.ims.nci.nih.gov
59. Litterst CL. Cisplatinum: A review, with special reference to cellular and molecular interactions. Agents Actions 1984;15:520-524.
60. Dimmitt DC, Shah AK, Arumugham T et al. Pharmacokinetics of oral and intravenous dolasetron mesylate in patients with renal impairment. J Clin Pharmacol 1998;38:798-806.
61. Palmer R. Efficacy and safety of granisetron (Kytril) in two special patient populations: Children and adults with impaired hepatic function. Semin Oncol 1994;21(suppl 5):22-25.
62. Figg WD, Dukes GE, Pritchard JF et al. Pharmacokinetics of ondansetron in patients with hepatic insufficiency. J Clin Pharmacol 1996;36:206-215.
63. Terrin BN, McWilliams NB, Maurer HM. Side effects of metoclopramide as an antiemetic in childhood cancer chemotherapy. J Pediatr 1984;104:138-140.
64. Allen JC, Gralla RJ, Reilly L et al. Metoclopramide: Dose-related toxicity and preliminary antiemetic studies in children receiving cancer chemotherapy. J Clin Oncol 1985;3:1136-1141.
65. Graham-Pole J, Weare J, Engel S et al. Antiemetics in children receiving cancer chemotherapy: A double-blind prospective randomized study comparing metoclopramide with chlorpromazine. J Clin Oncol 1986;4:1110-1113.
66. Mehta NH, Reed CM, Kulman C et al. Controlling conditioning-related emesis in children undergoing bone marrow transplantation. Oncol Nurs Forum 1997;24:1539-1544.
67. Roila F, Aapro M, Stewart A. Optimal selection of antiemetics in children receiving cancer chemotherapy. Support Care Cancer 1998;6:215-220.
68. Yarker YE, McTavish D. Granisetron. An update of its therapeutic use in nausea and vomiting induced by antineoplastic therapy. Drugs 1994;48:761-793.
69. Pinkerton CR, Jacobson SJ, Leclerc JM et al. IV granisetron in children receiving highly emetogenic chemotherapy. Eur J Cancer 1993;29A(suppl 6):S200a.
70. Craft AW, Eden OB, Price L et al. Safety and efficacy of granisetron as an antiemetic in children. Med Pediatr Oncol 1993;21:567.
71. Hahlen K, Zucker JM, Pinkerton CR et al. IV granisetron in children: A randomized comparison against chlorpromazine plus dexamethasone in prevention of ifosfamide-induced emesis. Proc Am Soc Clin Oncol 1993;12:465a.
72. Hahlen K, Quintana E, Pinkerton CR et al. A randomized comparison of intravenously administered granisetron versus chlorpromazine plus dexamethasone in the prevention of ifosfamide-induced emesis in children. J Pediatr 1995;126:309-313.
73. Koseoglu V, Kurekci AE, Sarici U et al. Comparison of the efficacy and side-effects of ondansetron and metoclopramide-diphenhydramine administered to control nausea and vomiting in children treated with antineoplastic chemotherapy: A prospective randomized study. Eur J Pediatr 1998;157:806-810.
74. Tucker G. Advances in understanding drug metabolism and its contribution to variability in patient response. Ther Drug Monit 2000;22:110-113.
75. Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 1997;32:210-258.
76. Brosen K. Drug interactions and the cytochrome P450 system. The role of cytochrome P450 1A2. Clin Pharmacokinet 1995;29(suppl 1):20-25.
77. 3 antagonists. Drug Metab Dispos 1996;24:602-609.
78. Bloomer JC, Baldwin SJ, Smith GJ et al. Characterisation of the cytochrome P450 enzymes involved in the in vitro metabolism of granisetron. Br J Clin Pharmacol 1994;38:557-566.
79. Dixon CM, Colthup PV, Serabjit-Singh CJ et al. Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans. Drug Metab Dispos 1995;23:1225-1230.
80. Villikka K, Kivisto KT, Neuvonen PJ. The effect of rifampin on the pharmacokinetics of oral and intravenous ondansetron. Clin Pharmacol Ther 1999;65:377-381.
81. Gilbert CJ, Petros WP, Vredenburgh J et al. Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancer. Cancer Chemother Pharmacol 1998;42:497-503.
82. Cagnoni PJ, Matthes S, Day TC et al. Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics. Bone Marrow Transplant 1999;24:1-4.